Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma

BACKGROUND: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity. Current Eastern Cooperative Oncology Group (ECOG) consensus guideline recommend ceasing BRAF inhibitors during RT. There is a lack of dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Smith, Jessica Louise, Carlino, Matteo Salvatore, Burmeister, Bryan, Pinkham, Mark Blayne, Fogarty, Gerald Blaise, Christie, David Robert Harry, Estall, Vanessa, Shackleton, Mark, Clements, Arthur, Wolfe, Rory, Thao, Le Thi Phuong, Paton, Elizabeth Jane, Steel, Victoria, Williams, Narelle Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379352/
https://www.ncbi.nlm.nih.gov/pubmed/34458597
http://dx.doi.org/10.1016/j.ctro.2021.08.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379352/
https://www.ncbi.nlm.nih.gov/pubmed/34458597
http://dx.doi.org/10.1016/j.ctro.2021.08.006

Ejemplares similares